Research programme: interleukin-1 receptor antagonists - Serodus

Drug Profile

Research programme: interleukin-1 receptor antagonists - Serodus

Alternative Names: SER-140; SER-140-T2D

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Phlogo
  • Developer Serodus
  • Class Peptides
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 18 Jan 2016 Serodus plans a preclinical study for Norway (Serodus pipeline, January 2016)
  • 11 Jan 2016 SER 140 is still in preclinical trials for Type 2 diabetes mellitus in Denmark
  • 28 Oct 2015 Serodus files for patent protection for SER 140 in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top